Cadila Healthcare Ltd - Company Report

February 2017 | 15 pages | ID: CAC15E69DE9EN
SRI KRISHNA BHARATHI KNOWLEDGE SERVICES (SKBKS)

Abstracts

'Cadila Healthcare Ltd- Company Profile & Financial Analysis' contains in depth information and data about the company and its operations. You will find information on the business structure, areas of operation, products and services offered by the company. It also comprises SWOT analysis, key ratios, historical financial data and insider’s view on financial stability and industrial ranking with financial forecasts for two- year period.

This report is a decisive resource for industry executives and stakeholders who are looking to access key information about 'Cadila Healthcare Ltd'. It helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format. SKBKS strictly follows a standardized research methodology to ensure high levels of data quality and these characteristics guarantee a unique report.

ABSTRACT

Zydus Cadila is a fully integrated, global healthcare provider, with strengths all along the pharmaceutical value chain. With a core competence in the field of healthcare, Zydus Cadila provides total healthcare solutions ranging from formulations, active pharmaceutical ingredients and animal healthcare products to wellness products.

Apart from its business in India the group operates through its subsidiaries in U.S., Europe (France & Spain) and high profile markets of Latin America and South Africa and has offices across 25 emerging markets.

RECENT DEVELOPMENTS

• Acquired six brands from global pharma major MSD and its subsidiaries
• Received final approval from the USFDA to market Tizanidine Hydrochloride Capsules
• Received approval from US FDA to initiate Phase II clinical studies of Saroglitazar Magnesium in patients suffering from Primary Biliary (PBC).
• Received regulatory approvals to launch tetravalent inactivated influenza vaccine for seasonal flu in India

REPORT HIGHLIGHTS

• Business description – A detailed description of the company’s operations and business divisions
• Corporate business strategies – Analyst’s summarization of the company’s business strategies
• Major products and services – A descriptive list of major products, services and brands of the company.
• Company history –Major milestones achieved by the company
• Stock details- Ticker code at BSE and NSE, Market capitalization, Share price, 52 week relative performance at BSE, share holding pattern for the recent quarter
• Major Mergers & Acquisitions trends-a descriptive strategic acquisitions done by the company during the course of operations
• Financial Analysis- Five year financial summary; financial performance analysis of the company- a yearly and quarterly
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements with 5 years history.
• Cost structure- Five year cost structure analysis as percentage of sales
• Industry and peer competitors – Competitive economic environment in the industry and comparative financial analysis of peers.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Recent developments and Investment-Includes recent activities and strategies followed by the company and investments done and planned for future
• Outlook- Outlook of the industry with growth drivers
• Analysts’ view on the company with forecast for two year period.
• Supplemented with graphs and tabular information wherever necessary

REASONS TO BUY

• Quickly enhance your understanding of 'Cadila Healthcare Ltd'
• Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
• Gain insight into the marketplace and a better understanding of internal and external factors which could impact the industry.
• Increase business/sales activities by understanding your competitors’ businesses better.
• Recognize potential partnerships and suppliers.
• Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.

Contents

1. OVERVIEW

2. BUSINESS SEGMENTS

3. OTHER BUSINESSES AND ALLIANCE

4. KEY STRENGTHS

5. BUSINESS STRATEGIES

6. NEW INITIATIVES

7. FINANCIALS OF CADILA HEALTHCARE LTD

Five year performance Analysis (FY2012-2016)
Annual performance Analysis (FY2016 vs FY2015)
  Formulation Business
  Other Businesses and Alliances
  Financial Performance
Quarterly performances Analysis (October-December 2016 vs October-December 2015)

8. COST STRUCTURE ANALYSIS AS PERCENTAGE OF NET INCOME

9. PEER COMPARISON ANALYSIS AS PERCENTAGE OF NET INCOME

v Competitors mentioned:
Glenmark Pharmaceuticals Ltd
Torrent Pharmaceuticals Ltd
GLoaxoSmithKline Pharmaceuticals Ltd
Ajanta Pharma Ltd

10. SWOT ANALYSIS

Strengths
Weaknesses
Opportunities
Threats

11. RECENT DEVELOPMENTS

12. FUTURE STRATEGIES

13. OUTLOOK AND ANALYST VIEW

List Of Tables

LIST OF TABLES- CADILA HEALTHCARE LTD

List of Key Employees
Stock Details
Share Holdings–Quarter ending December 2016
Integrated Business Model
Major Milestones
Five year Financial Summary (FY2012-2016)
Key Financial Ratios (FY2012-2016)
Quarterly Financials (October-December 2015 to October-December 2016)
Cost structure as percentage of net income (FY2012-FY2016)
Peer Comparison as percentage of Net income (FY2016)
Position in the market-Cadila
Heat Chart-Peers (FY2016)
Income Statement Forecast (FY2017 and FY2018)

List Of Figures

LIST OF FIGURES- CADILA HEALTHCARE LTD

Relative performance of Stock at BSE (Recent 52 Week period)
Company Performance (FY2012-FY2016)
Revenue Break up-FY2016
India Branded Formulations Sales-FY2016
Cost Structure as percentage of net Income (FY2016 vs FY2015)
Peers Performance (FY2016)